30 closest matches · ranked by relevance
Influenza, Human
Primary: Number of Seasonal Influenza A and /or B Cases by Age Group, in Panama (Using the Data Reported Via National Influenza Surveillance Program) — 448; 120; 123; 47…
Influenza · Influenza Vaccines
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer
Influenza A
Primary: Magnitude of Antibody Response After the Late-season 2023 Vaccine — 6; 6; 74; 27 HAI Titer
Influenza
Primary: Number of Subjects Boosted at Month 12 With Haemagglutinin-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 178 Participants
Interpandemic Influenza
Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…
Influenza
Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants
Pandemic · Avian Influenza
Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects
Influenza
Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
Influenza · Healthy
Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0.4; 0.0 percentage of participants
Influenza · Vaccines Adverse Reaction
Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation — 153 participants
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Influenza
Primary: Seroconversion — 29; 32; 37; 35 Number of subjects
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Influenza
Primary: Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab — 2; 4 participants — p=0.685
Influenza
Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Novel Influenza A/H1N1
Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation. — 234…
Influenza
Primary: Percentage of Participants Reporting Fever Within 7 Days Post Vaccination — 0.0; 1.7 Percentage of Participants
Influenza
Primary: Seroconversion — 27; 17; 32; 43 Subjects
Influenza Vaccines
Primary: Geometric Mean Titers (GMTs) of Anti-H3 and B Strains — 369.6; 331.2; 269.6; 245.0 Titer
Influenza · Healthy
Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0; 0.4 Percentage of Participant
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 6; 24; 21 Participants
Influenza
Primary: Seroconversion — 43; 50; 45; 48 Number of subjects
Influenza · Healthy
Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 1.7; 0.4 Percentage of participants
Influenza
Primary: Seroprotection — 65.5; 80.0; 98.2; 98.2 percentage of subjects
Influenza · Healthy
Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0; 0 Percentage of Participants
Influenza
Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs